News | March 06, 2015

Three-Year Data on Combo Dual Therapy Stent Featured at JIM 2015

Dual therapy stent uses abluminal drug delivery to accelerate natural healing of vessel wall

OrbusNeich, Combo Dual Therapy Stent, REMEDEE, EGO COMBO, JIM 2015

Image courtesy of OrbusNeich

March 6, 2015 — A three-year review of data on the Combo Dual Therapy Stent was presented at the Joint Interventional Meeting (JIM) 2015 in Rome. These data demonstrate the healing benefits of the Combo Dual Therapy Stent in the treatment of coronary artery disease in the short, medium and long-term.

The device’s unique endothelial progenitor cell (EPC) capture technology combined with abluminal drug delivery accelerates the natural healing of the vessel wall and provides clinical benefits throughout the healing process. The stent is recognized in the latest European Society of Cardiology/European Association of Cardio-thoracic Surgeons (ESC/EACTS) guidelines on myocardial revascularization.

Prof. Corrado Tamburino of Ferrarotto Hospital, Catania, Italy, presented results from the REMEDEE First In Man (FIM) and EGO COMBO trials, which monitored stent healing using optical coherence tomography (OCT), the highest resolution equipment available in the clinic. Stent coverage and neo-intimal thickness were evaluated, two important measures from which healing can be assessed.

In the short term, rapid strut coverage was shown from as early as two months; mid-term, neo-intimal proliferation was controlled and low rates of restenosis were reported, comparable to contemporary drug-eluting stents; and in the long-term, researchers reported stable and consistent healing, lower neo-intimal thickness compared with the other stent groups, and the absence of neoatherosclerosis.

“The consistent data on the Combo technology is promising,” said Tamburino. “What we have seen to date reflects what is being reported in clinical practice and the real-life difference it is making to the lives of patients. We look forward to seeing the results of the all of the Combo clinical trial programs which include over 5,500 patients.”

Tim Kinnaird, M.D., University Hospital of Wales, Cardiff, U.K., compared IVUS-VH (virtual histology intravascular ultrasound) with OCT imaging processes in a presentation entitled ‘Can Imaging Differentiate Dual Therapy Stent from Mono-therapy DES?’

“Advancements in imaging provide us with the opportunity to have new insights into stents,” said Kinnaird. “These advancements give us the opportunity to appreciate the advanced healing offered by Combo with its unique endothelial progenitor cell (EPC) capture technology, which translates to true vessel healing, compared with conventional monotherapy drug-eluting stents.”

The Combo Stent featured in live cases transmitted from the Columbus Hospital in Milano, Italy and Bonn University Hospital in Bonn, Germany.  From the Columbus University, the patient presented with a multi-vessel disease, a history of atrial fibrillation and impaired left ventricular function. A long, calcified and diffusely diseased left anterior descending artery was treated. From the Bonn University Hospital, the patient, a 67-year-old male with a history of type II diabetes, hypertension and poor AF was treated with. Both cases were successful.

For more information:

Related Content

ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study| June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study| August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init